Table Graph
      published meta-analysis   sensitivity analysis   studies

standard of care in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 2.33 [0.70; 7.77] 2.33[0.70; 7.77]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%331NAnot evaluable clinical improvementdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 1.22 [0.70; 2.13] 1.22[0.70; 2.13]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%331NAnot evaluable clinical improvement (14-day)detailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 1.22 [0.70; 2.13] 1.22[0.70; 2.13]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%331NAnot evaluable clinical improvement (7-day)detailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 1.12 [0.74; 1.71] 1.12[0.74; 1.71]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%331NAnot evaluable mechanical ventilationdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 0.65 [0.30; 1.42] 0.65[0.30; 1.42]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%331NAnot evaluable radiologic improvement (14-day)detailed resultsRashad A (AZI vs SoC), 2021 (REV) 0.61 [0.35; 1.07] 0.61[0.35; 1.07]Rashad A (AZI vs SoC), 2021 (REV)10%206NAnot evaluable serious adverse eventsdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 0.98 [0.20; 4.92] 0.98[0.20; 4.92]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%438NAnot evaluable adverse eventsdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 0.83 [0.56; 1.23] 0.83[0.56; 1.23]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%438NAnot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV) 0.74 [0.26; 2.12] 0.74[0.26; 2.12]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 (REV)10%331NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-29 00:13 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 651 - roots T: 651

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons